Neoplasms of the lung: Edited by Alan M. Fein and David OstMalignant mesothelioma 2008Zervos, Michael D; Bizekis, Costas; Pass, Harvey IAuthor Information Department of Cardiothoracic Surgery, Division of Thoracic Surgery, New York University School of Medicine, New York, USA Correspondence to Michael D. Zervos, MD, New York University School of Medicine, 530 First Avenue, Suite 9F, New York, NY 10016, USA Tel: +1 212 263 7102; e-mail: [email protected] Current Opinion in Pulmonary Medicine: July 2008 - Volume 14 - Issue 4 - p 303-309 doi: 10.1097/MCP.0b013e328302851d Buy Metrics Abstract Purpose of review Mesothelioma is an aggressive malignancy of the pleura with poor survival. There will be approximately 3000 cases of mesothelioma in the United States annually. Multimodality treatment including neoadjuvant chemotherapy in selected individuals followed by extrapleural pneumonectomy and radiation has been studied in recent trials for its effects on disease free and overall survival This review provides a general overview of malignant mesothelioma with a summary of the most significant articles from within the past year as well as from the past. Recent findings Areas of recent interest include the evaluation of osteopontin and mesothelin as new tumor markers for mesothelioma. New phase III trials have been performed to evaluate the use of combined chemotherapy regimens. Summary Malignant mesothelioma is a very difficult malignancy to treat. Patients with the disease usually have an occupational asbestos exposure, and in some, viral exposure with SV40. There have been many historical treatments including combinations of local control with surgery and radiation as well as attempts to prevent systemic failure with chemotherapy. Novel therapies including intrapleural chemotherapy, photodynamic therapy and hyperthermic perfusion have also been used with some success. Finally there are several attempts at immunomodulating and targeted treatments, which are in phase I/II trials. © 2008 Lippincott Williams & Wilkins, Inc.